Literature DB >> 3031741

Neutron therapy for malignant tumours of the salivary glands. A report of the Edinburgh experience.

W Duncan, J A Orr, S J Arnott, W J Jack.   

Abstract

A group of 28 patients with malignant tumours of the salivary glands have been treated by d(15) + Be neutron irradiation. Nineteen patients had inoperable cancers. Three had gross recurrent cancer and three had measurable residual cancer after surgery. Three patients were treated post-operatively for microscopic residual disease. Seven different histological types of tumour were included. Six out of 8 patients with adenoid cystic carcinomas have lasting local tumour control. 54.5% of the gross tumours were locally controlled. All three of those classified as microscopic residual disease have no evidence of local recurrence. 11/14 cancers given 16.0 Gy or more in 20 fractions in 4 weeks were controlled compared with only 1/8 given a lower dose. 12/19 cancers less than 10.0 cm maximum diameter were controlled. The radiation-related morbidity was similar to that observed after photon therapy.

Entities:  

Mesh:

Year:  1987        PMID: 3031741     DOI: 10.1016/s0167-8140(87)80162-7

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  Radiotherapy for parotid cancer.

Authors:  L M Toonkel; S Guha; P Foster; V Dembrow
Journal:  Ann Surg Oncol       Date:  1994-11       Impact factor: 5.344

2.  Three discipline collaborative radiation therapy (3DCRT) special debate: The United States needs at least one carbon ion facility.

Authors:  Eleanor A Blakely; Bruce Faddegon; Christopher Tinkle; Charles Bloch; Michael Dominello; Robert J Griffin; Michael C Joiner; Jay Burmeister
Journal:  J Appl Clin Med Phys       Date:  2019-10-01       Impact factor: 2.243

3.  Neutron exposures in human cells: bystander effect and relative biological effectiveness.

Authors:  Isheeta Seth; Jeffrey L Schwartz; Robert D Stewart; Robert Emery; Michael C Joiner; James D Tucker
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.